Stoke Therapeutics
STOK
100 hedge funds and large institutions have $495M invested in Stoke Therapeutics in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 42 increasing their positions, 27 reducing their positions, and 9 closing their positions.
1,610% more call options, than puts
Call options by funds: $3.03M | Put options by funds: $177K
56% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 27
44% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 9
33% more capital invested
Capital invested by funds: $372M → $495M (+$123M)
4.47% more ownership
Funds ownership: 100.86% → 105.33% (+4.5%)
4% more funds holding
Funds holding: 96 → 100 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.05M |
| 2 |
BlackRock
New York
|
+$4.77M |
| 3 |
CAC
Cowen and Company
New York
|
+$4.71M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.8M |
| 5 |
Millennium Management
New York
|
+$3.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$2.02M |
| 2 |
MCM
M28 Capital Management
Stamford,
Connecticut
|
-$1.99M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.56M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.18M |
| 5 |
JP Morgan Chase
New York
|
-$971K |
STOK Hedge Fund Activity: Q2 2023 in Review
100 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q2 2023, worth a combined $495M — up 33% from $372M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new STOK positions and 9 closed out — a net gain of 4 holders — while 42 added to existing stakes and 27 trimmed.
The largest buyer was Vanguard Group, adding an estimated $5.05M. The largest seller was Redmile Group, cutting an estimated $2.02M.
- 100 institutional investors held Stoke Therapeutics (STOK) as of Q2 2023, up from 96 in Q1 2023.
- Funds reported $495M of Stoke Therapeutics stock for Q2 2023, up 33% quarter-over-quarter.
- 13 funds opened new Stoke Therapeutics positions in Q2 2023 and 9 closed out, a net change of +4 holders.
- The largest Stoke Therapeutics buyer in Q2 2023 was Vanguard Group, an estimated $5.05M added.
- The largest Stoke Therapeutics seller in Q2 2023 was Redmile Group, an estimated $2.02M sold.
Based on aggregated 13F filings for Q2 2023.